Specialty drugmakers lobbying together

Here's a quandary: You're a good-sized drugmaker, but not a behemoth able to throw your weight around the industry's big trade associations. So how do you get your voice heard in our nation's capital? Form your own association, of course. That's exactly what Celgene, Cephalon, Cubist, Endo, Millennium, Purdue and Sepracor are doing: Banding together under the name America's Specialty Medicines Companies, and hiring a D.C. law firm for help getting organized.

What might this assortment's key issues be? That's unclear as yet. But you can bet we'll hear more from them as time goes by.

- read the item at In Vivo

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.